Compare WKEY & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WKEY | RFL |
|---|---|---|
| Founded | 1999 | 2017 |
| Country | Switzerland | United States |
| Employees | 202 | N/A |
| Industry | EDP Services | Real Estate |
| Sector | Technology | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.1M | 92.6M |
| IPO Year | N/A | 2017 |
| Metric | WKEY | RFL |
|---|---|---|
| Price | $7.49 | $2.57 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $10.50 | N/A |
| AVG Volume (30 Days) | 135.9K | ★ 230.3K |
| Earning Date | 01-28-2026 | 06-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $917,000.00 |
| Revenue This Year | $31.22 | N/A |
| Revenue Next Year | $91.39 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 43.96 |
| 52 Week Low | $4.75 | $1.12 |
| 52 Week High | $19.80 | $2.80 |
| Indicator | WKEY | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 44.41 | 75.69 |
| Support Level | $7.35 | $1.22 |
| Resistance Level | $8.22 | N/A |
| Average True Range (ATR) | 0.65 | 0.26 |
| MACD | -0.15 | 0.11 |
| Stochastic Oscillator | 15.35 | 79.33 |
WISeKey International Holding Ltd is a cybersecurity company focused on delivering integrated security solutions for the Internet of Things and digital identity ecosystems. It integrates secure semiconductors, cybersecurity software, and a globally recognized Root of Trust (RoT) into products and services that protect users, devices, data and transactions in the internet-connected world. It has two business segments. The IoT segment, which is the key revenue driver, generates revenue from the sale of semiconductor's secure chips. The mPKI segment generates revenues from Digital Certificates, It derives maximum revenue from IoT segment.
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.